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OBJECTIVE — Type 2 diabetes and impaired glucose metabolism (IGM) are associated with
an increased cardiovascular disease (CVD) risk. Increased left ventricular mass (LVM) is thought
to increase CVD risk through several unfavorable cardiac changes. Type 2 diabetes and IGM are
associated with increased LVM, but the underlying mechanism is unclear. We investigated the
association between glucose tolerance status (GTS) and LVM and explored whether any such
association could be mediated through increased arterial stiffness, impaired endothelial func-
tion, or the presence of atherosclerosis.
RESEARCH DESIGN AND METHODS — We used ultrasound to measure LVM, ca-
rotid and femoral stiffness, carotid-femoral transit time, and flow-mediated vasodilation (FMD)
and tonometry to estimate compliance and augmentation index. The study population (n 780)
consisted of 287 individuals with normal glucose metabolism (NGM), 179 with IGM, and 314
with type 2 diabetes, and the mean age was 68.4 years.
RESULTS — In women, after adjusting for age, height, BMI, and mean arterial pressure, LVM
increased significantly with deteriorating GTS (LVM 157 g in NGM, 155 g in IGM, and 169 g in
type 2 diabetes; P for trend 0.018). Additional adjustment for arterial stiffness, FMD, or the
presence of atherosclerosis did not materially alter the results, even though these variables were
significantly associated with both GTS and LVM. Indexes of hyperglycemia/-insulinemia or
insulin resistance explained at most 7% of the association between GTS and LVM. In men, no
statistically significant associations were observed.
CONCLUSIONS — Our data expand the conceptual view of the pathogenesis of GTS-related
changes in LVM because we show that the increase in LVM in women is independent of increased
arterial stiffness, impaired FMD, or the pres-
ence of atherosclerosis. In addition, we show
that this increase in LVM is only minimally
explained by indexes of hyperglycemia/-
insulinemia or insulin resistance. Our data
may, in part, explain the increased CVD risk
seen in women with deteriorating GTS.
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C ardiovascular disease (CVD) ac-counts for most of the morbidityand mortality in type 2 diabetes. An
increased CVD risk is already present in
individuals with impaired glucose metab-
olism (IGM), i.e., impaired fasting glucose
and/or impaired glucose tolerance (1),
and is not accounted for by conventional
risk factors.
Increased left ventricular mass (LVM)
is thought to increase CVD risk through a
series of unfavorable metabolic, func-
tional, and structural cardiac changes (2–
4). For example, increased LVM increases
the risk of myocardial infarction and heart
failure by enhancing myocardial oxygen
consumption and by impeding diastolic
left ventricular compliance. Several stud-
ies have shown that deteriorating glucose
tolerance is associated with increased
LVM (5–14). The mechanisms responsi-
ble for this association remain unclear,
but hyperglycemia/-insulinemia and the
insulin-resistant state have been impli-
cated in the pathogenesis of increased
LVM (14–18).
However, the harmful effects of dete-
riorating glucose tolerance are not limited
to the myocardium, and a variety of both
structural and functional maladaptive al-
terations along the arterial tree have been
reported in IGM and type 2 diabetes. We
have previously shown that deteriorating
glucose tolerance status (GTS) is associ-
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ated with increased carotid, femoral, and
brachial arterial stiffness (as measured by
distensibility, compliance, and elastic
modulus) (19) and with impaired endo-
thelial function (as measured by flow-
mediated vasodilation [FMD] of the
brachial artery) (R.M.A.H., P.J.K., J.M.D.,
G.N., R.J.H., O.K., L.M.B., C.D.A.S., un-
published observations). Increased arte-
rial stiffness can contribute to increases in
LVM by elevating cardiac afterload, where
the increase in LVM can be viewed as an
adaptive response to keep left ventricular
wall stress constant and preserve left ven-
tricular systolic function (20,21). Endo-
thelial dysfunction may contribute to
increases in LVM by loss of the inhibitory
role of nitric oxide on the synthesis of ex-
tracellular matrix components (22) and
by shifting the local vasodilator (nitric ox-
ide)/vasoconstrictor (endothelin) balance
toward endothelin, a molecule with spe-
cific cardiac myocyte growth-promoting
properties (23).
In view of these considerations, we
hypothesized that increased LVM occurs
not only in type 2 diabetes but also in IGM
and is mediated, at least in part, by a glu-
cose intolerance–associated increase in
arterial stiffness and impairment of endo-
thelial function. We investigated these
hypotheses in a population-based cohort.
RESEARCH DESIGN AND
METHODS — For the present investi-
gation, we used data from the 2000
Hoorn Study follow-up examination (19)
and the Hoorn Screening Study (24).
Briefly, the Hoorn Study is a study of glu-
cose metabolism in the general popula-
tion (n 2,484) that started in 1989 (25).
In 2000, a follow-up examination was
carried out among all surviving partici-
pants. We invited all those who had dia-
betes, as determined by an oral glucose
tolerance test or who were treated for di-
abetes at the 1996 follow-up (n  176).
We also invited random samples of indi-
viduals with normal glucose metabolism
(NGM) (n 705) and IGM (n 193). Of
1,074 individuals thus invited, 648
(60%) participated. Additionally, we in-
vited 217 individuals with type 2 diabetes
from the Hoorn Screening Study (24), of
whom 188 (87%) participated. Data on
14 individuals were missing due to logis-
tical problems. The study population
(n 822) thus consisted of three groups:
290 with NGM, 187 with IGM, and 345
with type 2 diabetes. The study was ap-
proved by the local ethics committee. All
participants gave their written informed
consent.
Among the 455 nonparticipants
(53% women), 13% were complete non-
responders. The remaining nonpartici-
pants gave various reasons not to
participate: lack of interest (30%), comor-
bidity (23%), age (7%), unwillingness to
travel (6%), participation too time con-
suming (6%), and miscellaneous reasons
(15%).
Echocardiography
An experienced research technician un-
aware of the participants’ clinical status or
GTS obtained an echocardiogram in each
participant, according to a standardized
protocol, with the use of a single ultra-
sound scanner (HP SONOS 5500;
Hewlett Packard, Andover, MA). M-mode
recordings were digitally stored and read
according to the guidelines of the Ameri-
can Society of Echocardiography (26).
Left ventricular end-diastolic diame-
ter (EDD), posterior wall thickness
(PWT), and interventricular septum
thickness (IVS) were measured at end di-
astole. LVM was calculated as 0.8(1.04)
([EDD  IVS  PWT]3  EDD3)  0.6
(in grams) and relative wall thickness
(RWT) as (IVS  PWT)/EDD (27) Each
echocardiogram was inspected afterward
by a senior cardiologist blinded to the
participants’ clinical status or GTS in or-
der to monitor the quality of both record-
ings and readings. Left ventricular
geometric patterns were classified accord-
ing to Heesen et al. (28).
Arterial stiffness
Carotid and femoral arterial stiffness in-
dexes were determined by ultrasonogra-
phy, us ing previous ly descr ibed
techniques (19) and calculated as follows.
Distensibility coefficient  (2D  D 
D2)/(P  D2) (in 103  kPa1); com-
pliance coefficient   (2D  D 
D2)/(4  P) (in mm2  kPa1); and
Young’s elastic modulus  D/(intima-
media thickness  distensibility coeffi-
cient) (in kPa). D is distension, D is
diameter, and P is local pulse pressure.
Local pulse pressures were determined
with the use of distension waveform cali-
bration (29). The distensibility coefficient
reflects the arterial elastic properties,
whereas the compliance coefficient re-
flects the arterial buffering capacity and
Young’s elastic modulus indicates the in-
trinsic elastic wall properties (30).
Systemic arterial compliance (ml/
mmHg) was determined according to the
exponential decay method (31) and the
augmentation index from pressure wave
analysis (32), both with the use of tonom-
etry-derived aortic pressure waveforms
(Sphygmocor, Moreton-in-Marsh, U.K.),
as previously described (33). Systemic ar-
terial compliance and the augmentation
index represent the overall buffering ca-
pacity of the arterial system and the over-
all stiffness of the arterial system,
respectively, taking into account the con-
tribution of reflected (backward) pulse
waves to aortic blood pressure.
The carotid-femoral transit time (in
ms) was determined with the use of the
ultrasonically recorded carotid and femo-
ral distension wave forms (33) and repre-
sents the average stiffness over the aortic
segment.
Endothelial function
We measured brachial artery endotheli-
um-dependent vasodilation and the pres-
ence of atherosclerosis (both as defined
below) as proxies for coronary artery en-
dothelium-dependent vasodilation
(34,35).
Brachial artery flow–mediated
dilation
All individuals underwent an ultrasound
examination according to guidelines of
the International Brachial Artery Reactiv-
ity Task Force (36). Briefly, baseline arte-
rial diameter and peak flow velocity were
determined. A blood pressure cuff was
placed on the forearm, inflated, and kept
constant at supra-systolic pressure to in-
duce forearm ischemia. After 5 min, the
cuff was released, resulting in an increase
in arterial blood flow. This increase in
blood flow increased shear stress, which
served as the stimulus for flow-mediated
dilation. After cuff release, maximum
peak flow velocity was measured within
15 s and arterial diameter at 45, 90, 180,
and 300 s. The maximum diameter in any
of these four measurements was used in
statistical analysis. After 15 min of rest to
reestablish arterial baseline conditions,
endothelium-independent, nitroglycerin-
mediated dilation was determined as fol-
lows: baseline arterial diameter and peak
flow velocity were redetermined. Nitro-
glycerin (400 g, Nitrolingual Spray;
Pohl-Boskamp, Hohenlockstedt, Ger-
Henry and Associates
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many) was then sublingually adminis-
tered; after 5 min, arterial diameter and
peak flow velocity were again deter-
mined.
Other measurements
Health status, medical history, medica-
tion use, and smoking habits were as-
sessed by a questionnaire (25). Systolic
and diastolic pressure; pulse pressure; hy-
pertension; glucose; HbA1c; serum total,
HDL, and LDL cholesterol; serum triglyc-
erides; BMI; waist-to-hip ratio; mi-
croalbuminuria; and ankle-brachial
pressure index were determined as de-
scribed elsewhere (24,25). Insulin resis-
tance was calculated according to the
homeostasis model assessment (37). Rest-
ing electrocardiograms were coded ac-
cording to the Minnesota Code. Prior
CVD was defined as Minnesota Code 1.1–
1.3, 4.1–4.3, 5.1–5.3, or 7.1 on the elec-
t rocard iogram, coronary bypass
operation or angioplasty, and/or periph-
eral arterial bypass or amputation. The
presence of prior CVD, peripheral arterial
disease as defined by an ankle-brachial
pressure index0.9, and/or a carotid in-
tima-media thickness	1.05 mm (i.e., the
90th percentile of the distribution in in-
dividuals with NGM) was considered to
indicate the presence of atherosclerosis.
Reproducibility
Reproducibility was assessed in 10 indi-
viduals (5 men; age 58.2
 9.5 years) who
were examined twice at 2-week intervals.
The intraobserver intersession coeffi-
cients of variation ([SD of the difference/
2]/pooled mean) were distensibility
coefficients 7.0% (carotid), 11.3% (femo-
ral), and 12.8% (brachial); compliance
coefficients 6.3% (carotid), 13.1% (femo-
ral) and 13.9% (brachial); carotid elastic
modulus 11.6%; carotid-femoral transit
time 4.4%; aortic augmentation index
3.6%; systemic arterial compliance 8.3%;
and endothelium-dependent and -inde-
pendent dilation, expressed as absolute
diameter, 14.7 and 10.3%.
Statistical analysis
All analyses were carried out with SPSS
(SPSS, Chicago, IL). We used ANCOVA
with linear contrast to investigate trends
in left ventricular mean values across the
categories of glucose tolerance. All statis-
tically significant trends were tested
whether they deviated from linearity. The
associations between glucose tolerance
and the measurements of cardiac struc-
ture and geometry were examined sepa-
rately for men and women because, out of
five previous population-based studies
(5,7,9,11,12), three reported strong sex-
specific differences (5,9,11), particularly
so for LVM.
We first analyzed the associations
without any adjustments (crude model)
and then with adjustments for potential
confounders (adjusted models). Because
left ventricular structure is known to be
affected by age, height, BMI, and blood
pressure (38), these variables were con-
sidered first in the adjusted models. Arte-
rial stiffness indexes, FMD, and the
presence of atherosclerosis were then sep-
arately added into the models, as were es-
timates of hyperglycemia/-insulinemia
and insulin resistance.
Individuals with impaired fasting glu-
cose (n  63) and impaired glucose tol-
erance (n  116) did not significantly
differ from each other with regard to any
of the analyses and were therefore com-
bined. P values 0.05 were considered
statistically significant.
RESULTS
Ultrasound examinations
In 42 of the 822 participants, LVM could
not be determined due to either a high
BMI (n  33; BMI of those with qualita-
tively satisfactory examinations versus
those without, 27.5
 3.8 vs. 37.9
 8.9
kg/m2, P 0.001) or a poor transthoracic
window (n  9). In the remaining 780
individuals, carotid and femoral stiffness
indexes and FMD could be determined in
739, 648, and 636 individuals, respec-
tively. The main reason for missing arte-
rial data was poor definition of the arterial
wall due to obesity (BMI of those with
qualitatively satisfactory examinations
versus those without, 26.9 
 3.3 vs.
30.5 
 4.5 kg/m2, P  0.001).
Baseline characteristics
Table 1 shows the characteristics of the
entire study population. Both IGM and
type 2 diabetes were characterized by a
worsening cardiovascular risk factor pro-
file compared with NGM.
Glucose tolerance and left
ventricular structure: crude
associations
In women, LVM increased significantly
with deteriorating glucose tolerance (P for
trend 0.001) (Table 2). Similar trends
could be observed for EDD, PWT, and
IVS. RWT did not show any significant
trend (P for trend 0.358). The propor-
tion of women with a normal geometric
pattern decreased significantly with dete-
riorating glucose tolerance (P for trend
0.002), whereas the proportions of
women with either eccentric or concen-
tric hypertrophy increased significantly
(P for trend  0.042 and 0.039, respec-
tively). No statistically significant trend
was observed for concentric remodeling.
In men, neither the measures of left ven-
tricular structure nor the distribution of
geometric patterns showed any signifi-
cant trends with deteriorating glucose tol-
erance (Table 2).
Glucose tolerance and left
ventricular structure: adjusted
associations
In women, after adjustment for age,
height, BMI and mean arterial pressure,
glucose tolerance remained statistically
significantly associated with increased
LVM (P for trend 0.018) (Table 3,
model 2). Additional adjustment for ca-
rotid distensibility, FMD, and the pres-
ence of atherosclerosis did not materially
change the results (P for trend  0.030,
0.043, and 0.028, respectively, models
3–5), even though carotid distensibility,
FMD, and the presence of atherosclerosis
were significantly associated with GTS
(Table 1) and, after adjustment for age
and mean arterial pressure, LVM (data not
shown). A similar pattern could be ob-
served for the association between glu-
cose tolerance and end diastolic diameter
(models 1–5).
Different effects were observed for
PWT, IVS, and RWT. The associations be-
tween glucose tolerance and both PWT
and IVS were not statistically significant
after adjustment for age, height, BMI, and
mean arterial pressure (Table 3, models 1
and 2), whereas no significant associa-
tions, either crude or adjusted, could be
observed between GTS and RWT (RWT,
models 1–5). Additional investigations to
explore the individual impact of the vari-
ables age, height, BMI, and mean arterial
pressure revealed that the associations of
GTS with PWT and left ventricular wall
thickness were rendered insignificant af-
ter adjustment for mean arterial pressure,
whereas the association with IVS thick-
ness was rendered insignificant after ad-
Glucose tolerance and LV structure
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justment for BMI (detailed data not
shown).
In men, neither crude (P for trend, all
0.096) nor adjusted (P for trend, all
0.218) analyses showed statistically sig-
nificant associations between GTS and
ventricular structure. Nevertheless, the P
value for interaction (sex times GTS) was
not significant (P  0.11).
Results were similar when BMI was
replaced by waist-to-hip ratio and when
mean arterial pressure was replaced by
systolic, diastolic, or pulse pressure (de-
tailed data not shown). If we replaced IVS
or PWT by left ventricular wall thickness,
i.e., the sum of both, the crude association
with glucose tolerance lost significance af-
ter adjustment for the variables of model 2
(detailed data not shown). Results were
also similar when carotid distensibility
was replaced by other carotid or femoral
stiffness indexes or by systemic arterial
compliance, augmentation index, or the
carotid-femoral transit time (data not
shown).
Our study population was too small
to further explore any underlying mecha-
nisms between glucose tolerance and ven-
tricular geometry.
Impact of glucose, insulin, and
insulin resistance on LVM
To estimate the contribution of hypergly-
cemia/-insulinemia or insulin resistance
to the increase in LVM associated with
IGM and type 2 diabetes, we compared
the LVM analyses (adjusted for age,
height, BMI, and mean arterial pressure)
with those additionally adjusted for
HbA1c (or fasting or postload glucose), in-
sulin, and insulin resistance. This showed
that in women, at most 7% of the associ-
ation between glucose tolerance and LVM
could be explained by indexes of hyper-
glycemia/- insul inemia or insul in
resistance.
Additional analyses
Additional adjustment for brachial stiff-
ness indexes, heart rate, lipid profile, the
use of lipid-lowering or antihypertensive
medication including ACE inhibitors,
smoking, or (micro-)albuminuria did not
materially alter our results (detailed data
not shown). Results were also not materi-
ally altered if we excluded individuals
with left ventricular wall motion abnor-
malities (n  55) (data not shown). Fi-
nally, if we replaced LVM mass (in grams)
by LVM index, i.e., LVM divided by body
surface area (in grams per meters
squared), our results were again not al-
tered (data not shown).
CONCLUSIONS — The present pop-
ulation-based study on the association be-
tween glucose tolerance and cardiac
structure had three main findings. First,
glucose tolerance was independently as-
sociated with increased LVM in women,
but not clearly so in men. Second, the
association between glucose tolerance
and LVM in women was not mediated by
glucose intolerance–associated increased
arterial stiffness and impaired endothelial
function. Third, indexes of hyperglyce-
mia/-insulinemia or insulin resistance ex-
plained at most 7% of the association
between glucose tolerance and LVM.
Our study extends previous popula-
tion-based investigations (5–7,9,11,12),
as we are the first to examine the impact of
arterial stiffness and endothelial function
on the association between glucose toler-
ance and cardiac structure. In addition, to
be able to sufficiently adjust for potential
confounders, we extensively character-
ized our study population in terms of
CVD risk factors, prior CVD, and glucose
metabolism.
Our results are in general agreement
with previous population-based studies
on the association between glucose toler-
ance and LVM (5,7,9,11,12). However, it
is currently unclear whether (5,9,11) or
not (7,12) this association is stronger in
women than in men. In our investigation,
the statistical test for interaction between
sex and glucose tolerance on LVM was
P  0.11. Therefore, the result of our in-
teraction analysis neither excluded nor
proved the existence of a sex-specific
association.
We suggest that the independent as-
sociation we report between glucose tol-
erance and EDD, as well as the absence of
such an association with IVS or PWT, may
be explained by the fact that individuals
with type 2 diabetes are characterized by
an expanded extracellular volume (39),
which has been shown to increase left
ventricular chamber size relatively more
than myocardial wall thickness (40).
However, it remains poorly understood
Table 2—Sex-specific characteristics of left ventricular structure according to GTS
Left ventricular structure
Women Men
NGM IGM
Type 2
diabetes
P for
trend NGM IGM
Type 2
diabetes
P for
trend
M-mode measurement
Mass 147 
 37 163 
 48 176 
 51 0.001 188 
 55 187 
 59 199 
 66 0.096
EDD 4.78 
 0.48 4.94 
 0.56 4.99 
 0.52 0.001 5.22 
 0.60 5.17 
 0.61 5.30 
 0.58 0.223
Posterior wall thickness 0.85 
 0.14 0.89 
 0.15 0.92 
 0.16 0.001 0.92 
 0.14 0.94 
 0.16 0.93 
 0.17 0.394
IVS 0.93 
 0.21 0.96 
 0.22 1.00 
 0.26 0.018 1.00 
 0.23 0.99 
 0.25 1.02 
 0.25 0.327
RWT 0.38 
 0.09 0.38 
 0.09 0.39 
 0.09 0.358 0.37 
 0.09 0.38 
 0.10 0.37 
 0.09 0.953
Geometric pattern
Normal geometry 83.8 77.8 73.2 0.002 76.8 71.9 74.5 0.709
Concentric remodeling 13.5 15.6 14.1 0.931 11.6 16.9 9.7 0.572
Eccentric hypertrophy 1.4 5.6 6.7 0.042 7.2 4.5 7.9 0.791
Concentric hypertrophy 1.4 1.1 6.0 0.039 1.3 6.7 7.9 0.251
All M-mode measurements are given in centimeters (means 
 SD), except for mass, which is given in grams. Geometric patterns are expressed as percentages of
individuals within the glucose tolerance category. Normal geometry, RWT 0.45 and LVM index125 g/m2; concentric remodeling, RWT0.45 and LVM index
125 g/m2; eccentric hypertrophy, RWT 0.45 and LVM index 125 g/m2; concentric hypertrophy, RWT 0.45 and LVM index 125 g/m2.
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why the left ventricle apparently remodels
differentially over its regions (41), al-
though local dispersion of ventricular
pressure, ventricular flow patterns (42),
and (sex-specific) nonhemodynamic fac-
tors are thought to play a role (43,44) in
addition to specific, diabetes-associated
alterations in cardiac structure (5,7,9,12).
Taken together, these (5–7,9,12) and the
present data show that the left ventricle is
subject to maladaptive alterations with
deteriorating glucose tolerance, especially
in women. This sex-specific increase in
LVM may explain, at least in part, the in-
creased CVD risk in women with type 2
diabetes (45).
Our study showed that increased ca-
rotid and femoral arterial stiffness, or any
of the other stiffness indexes, influenced
the association between glucose tolerance
and measurements of cardiac structure
only minimally, despite the fact that dete-
riorating glucose tolerance was associated
with increased arterial stiffness (19) and
that increased arterial stiffness was asso-
ciated with increased LVM. The associa-
tion between glucose tolerance and LVM
was also not explained by impairment of
endothelial function, as estimated by bra-
chial artery FMD and the presence of ath-
erosclerosis, even though deteriorating
glucose tolerance was associated with im-
paired endothelial function, which in
turn was associated with increased LVM.
Decreased endothelial synthesis or bio-
availibility of nitric oxide may contribute
to increases in LVM by loss of its orches-
trating role in the synthesis of extracellu-
lar matrix components and by shifting the
local myocardial homeostasis toward hy-
pertrophy (22,23,46). Our results there-
fore suggest that other pathophysiological
mechanisms may play a role, such as in-
creased oxidative and carbonyl stress
(47), chronic low-grade inflammation
(48), and(or) autonomic neuropathy
(49). We cannot exclude, however, that
the methods we used are insufficiently
precise estimates of coronary endothelial
function, which, however, is difficult to
directly measure in large-scale studies.
Hyperglycemia/-insulinemia and in-
sulin resistance have been implicated in
the development of increased LVM (15–
18). In our study, the association between
GTS and LVM could only be explained to
a minor extent (7%) by any of these
Table 3—Sex-specific adjusted analyses of left ventricular structure
Model
Women Men
NGM IGM
Type 2
diabetes
P for
trend NGM IGM
Type 2
diabetes
P for
trend
Left ventricular mass (g)
1 147 163* 176†‡ 0.001 188 187 199‡ 0.096
2 157 155 169†‡ 0.018 195 184 193 0.843
3 156 155 167‡ 0.030 194 180 182 0.760
4 154 154 164‡ 0.043 191 177 188 0.703
5 157 155 169†‡ 0.028 195 184 193 0.756
EDD (cm)
1 4.78 4.94* 4.99‡ 0.001 5.22 5.17 5.30 0.223
2 4.82 4.90 4.97‡ 0.021 5.26 5.17 5.27 0.884
3 4.80 4.86 4.95‡ 0.020 5.23 5.11 5.27 0.601
4 4.80 4.85 4.96‡ 0.018 5.22 5.09 5.25 0.736
5 4.82 4.90 4.97‡ 0.022 5.26 5.17 5.27 0.887
Posterior wall thickness (cm)
1 0.85 0.89 0.92‡ 0.001 0.92 0.94 0.93 0.394
2 0.88 0.87 0.90 0.300 0.94 0.93 0.92 0.321
3 0.88 0.88 0.89 0.619 0.93 0.92 0.91 0.245
4 0.88 0.88 0.88 0.632 0.93 0.92 0.91 0.440
5 0.88 0.87 0.89 0.386 0.94 0.93 0.92 0.271
IVS (cm)
1 0.93 0.96 1.00‡ 0.18 1.00 0.99 1.02 0.327
2 0.97 0.93 0.97 0.978 1.02 0.98 1.01 0.663
3 0.97 0.94 0.95 0.676 1.02 0.96 0.99 0.274
4 0.96 0.93 0.95 0.625 1.02 0.97 0.99 0.427
5 0.97 0.93 0.97 0.910 1.02 0.98 1.00 0.651
RWT
1 0.38 0.38 0.39 0.358 0.37 0.38 0.37 0.953
2 0.39 0.37 0.38 0.412 0.38 0.38 0.37 0.447
3 0.39 0.38 0.38 0.219 0.38 0.37 0.36 0.218
4 0.39 0.38 0.37 0.225 0.38 0.38 0.37 0.391
5 0.39 0.38 0.38 0.341 0.38 0.38 0.37 0.436
Model 1, crude; model 2, adjusted for age, height, BMI, and mean arterial pressure; model 3, adjusted for variables of model 2 plus carotid distensibility; model 4,
model 2 plus adjusted for endothelial function; model 5, model 2 plus adjusted for the presence of atherosclerosis. *IGM significantly different from NGM; †type
2 diabetes significantly different from IGM; ‡type 2 diabetes significantly different from NGM; all P values  0.05.
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variables. These observations are in line
with several previous (population-based)
studies (5,50–53) However, conflicting
results have been published in relatively
small, select, non–population-based in-
vestigations (15–18) and one population-
based inves t iga t ion among non-
Caucascian individuals (14).
Our study had several limitations.
First, it should be kept in mind that the
cross-sectional nature of our data does
not allow us to make strong causal infer-
ences. Second, our results might have
been influenced by the coexistence of
CVD affecting left ventricular shape.
However, it has been shown that LVM can
be estimated accurately from M-mode
echocardiography, even in the presence
of CVD (27). Nevertheless, to circumvent
this possibility, we adjusted for CVD in
our analyses. Third, due to the rapid re-
sponsiveness of the body to hormonal and
metabolic changes, determination of in-
sulin resistance by homeostasis model as-
sessment method is subject to biological
variability, which might have weakened
its association with LVM. However, rec-
ommendations (37) made to diminish
this source of variation are not easily ap-
plicable in large population-based stud-
ies. Finally, our results were obtained in a
relatively elderly Caucasian population,
and therefore, it remains to be determined
whether our results can be generalized to
other ages and ethnicities (14).
In conclusion, our data expand the
conceptual view of the pathogenesis of
glucose tolerance–related changes in
LVM, as we show that the increase in LVM
in women is independent of increased ar-
terial stiffness, impaired FMD, or the
presence of atherosclerosis. In addition,
we show that this increase in LVM is only
minimally explained by indexes of hyper-
glycemia/-insulinemia or insulin resis-
tance. Our data may explain, in part, the
increased CVD risk seen in women with
deteriorating glucose tolerance.
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